

BBS-Bioactive Bone Substitutes Plc

Financial Statement 30th June 2018

BBS-Bioactive Bone Substitutes Plc CONSOLIDATED INCOME STATEMENT	1.1.-30.6.2018	1.1.-30.6.2017	1.1.-31.12.2017
Other operating income	*2 237 121,94	13 879,38	20 466,26
Materials and services			
Raw material and consumables			
Purchase during the period	-57 557,54	-21 173,15	-26 701,80
External services	-46 912,67	-48 046,39	-74 540,76
Raw materials and services total	-104 470,21	-69 219,54	-101 242,56
Personnel expenses			
Wages and salaries	-309 625,69	-251 849,08	-524 596,08
Social security expenses			
Pension expenses	-44 176,05	-22 026,27	-60 885,63
Other personnel expenses	-2 577,59	-9 816,91	-17 648,14
Personnel expenses total	-356 379,33	-283 692,26	-603 129,85
Depreciation and amortization			
Depreciation according to plan	-112 241,02	-106 284,85	-212 569,70
Impairment of non-current assets	0,00	0,00	-2 950 000,00
Depreciation and amortization total	-112 241,02	-106 284,85	-3 162 569,70
Other operating expenses	-588 043,76	-170 361,89	-517 346,31
OPERATING PROFIT (LOSS)	1 075 987,62	-615 679,16	-4 363 822,16
Financial income and expenses			
Other interest income and other financing income			
From others	1,65	1,71	3,28
Other interest and financial expenses			
To others	-51 389,91	-50 012,47	-102 495,89
Financial income and expenses total	-51 388,26	-50 010,76	-102 492,61
PROFIT (LOSS) BEFORE APPROPRIATIONS AND TAXES	1 024 599,36	-665 689,92	-4 466 314,77
PROFIT (LOSS) OF THE FINANCIAL PERIOD	1 024 599,36	-665 689,92	-4 466 314,77

*The accord from old loans improved the result by EUR 2,22 million

BBS-Bioactive Bone Substitutes Plc
CONSOLIDATED BALANCE SHEET

	30.6.2018	30.6.2017	31.12.2017
ASSETS			
NON-CURRENT ASSETS			
Intangible assets			
Development expenditure	7 532 827,55	10 482 827,55	7 532 827,55
Other Intangible assets	470 306,35	544 340,76	507 323,56
Intangible assets total	8 003 133,90	11 027 168,31	8 040 151,11
Tangible assets			
Land and water areas	83 719,00	83 719,00	83 719,00
Buildings and structures	575 183,34	618 476,72	596 044,92
Machinery and equipment	812 793,14	848 705,53	853 464,68
Tangible assets total	1 471 695,48	1 550 901,25	1 533 228,60
NON-CURRENT ASSETS TOTAL	9 474 829,38	12 578 069,56	9 573 379,71
CURRENT ASSETS			
Debtors			
Short term			
Other debtors	69 436,88	2 831,36	57 520,51
Prepayments and accrued income	1 496,98	21 646,57	2 494,91
Short term debtors total	70 933,86	24 477,93	60 015,42
Debtors total	70 933,86	24 477,93	60 015,42
Cash and equivalents	2 269 877,20	144 786,76	35 388,02
CURRENT ASSETS TOTAL	2 340 811,06	169 264,69	95 403,44
ASSETS TOTAL	11 815 640,44	12 747 334,25	9 668 783,15

BBS-Bioactive Bone Substitutes Plc
CONSOLIDATED BALANCE SHEET

30.6.2018

30.6.2017

31.12.2017

EQUITY AND LIABILITIES

CAPITAL AND RESERVES

Equity			
Share capital	80 000,00	27 984,01	80 000,00
Equity total	80 000,00	27 984,01	80 000,00
Share premium account	1 394 957,01	1 394 957,01	1 394 957,01
Other reserves			
Invested unrestricted equity fund	11 337 847,26	7 377 028,75	7 836 992,76
Other reserves total	11 337 847,26	7 377 028,75	7 836 992,76
Retained earnings (loss)	-8 775 902,76	-4 309 587,99	-4 309 587,99
Profit (loss) of the period	1 024 599,36	-665 689,92	-4 466 314,77
CAPITAL AND RESERVES TOTAL	5 061 500,87	3 824 691,86	536 047,01

CREDITORS

Long term			
Capital loans	175 825,46	950 000,00	950 000,00
Loans from credit institutions	6 048 145,33	7 251 927,00	6 722 719,60
Long term loans total	6 223 970,79	8 201 927,00	7 672 719,60
Short term			
Loans from credit institutions	122 648,67	368 843,00	898 050,40
Trade creditors	60 692,92	11 992,45	124 029,05
Other creditors	731,40	2 786,16	100 730,32
Accrual and referred income	346 095,79	337 093,78	337 206,77
Short term creditors total	530 168,78	720 715,39	1 460 016,54
CREDITORS TOTAL	6 754 139,57	8 922 642,39	9 132 736,14

EQUITY AND LIABILITIES TOTAL

11 815 640,44

12 747 334,25

9 668 783,15

BBS-Bioactive Bone Substitutes Plc.

CASH FLOW STATEMENT 30th June

BBS-Bioactive Bone Substitutes Plc Concern

	[thousand euros]	1-6/2018	1-6/2017	2017
Cash flow from business operations				
Profit (loss) before extraordinary items		1025	-666	-4466
Adjustments				
Scheduled depreciation and amortization		112	106	213
financial income and expenses		51	50	102
Other adjustments: Accord of loans		-2224	0	0
other adjustments: Write-downs		0	0	2950
Cash flow before changes in working capital		-1036	-510	-1201
Change in working capital				
Changes in short-term non-interest-bearing receivables Increase(-)/Decrease(+)		-11	-20	-56
Changes in inventory Increase(-)/Decrease(+)		0	0	0
Changes in short-term non-interest-bearing loans Increase(+)/Decrease(-)		-22	123	265
Cash flow from business operations before financial items and taxes		-1069	-407	-992
Interest paid and other financial expenses from business operations		84	17	102
Interest received and other financial income from business operations		0	0	0
Cash flow before extraordinary items		-1153	-424	-1094
Cash flow from business operations (A)		-1153	-424	-1094
Cash flow from investments				
Investments in tangible and intangible goods		-13	0	-52
Investments in shares in subsidiaries		0	0	0
Loans granted		0	0	0
Cash flow from investments (B)		-13	0	-52
Cash flow from financing				
Rights issue		3501	445	957
Raised long-term loans		0	0	0
Repayment of long-term loans		0	0	0
Raised short-term loans		0	0	100
Repayment of short-term loans		100	0	0
Cash flow from financing (C)		3401	445	1057
Changes in funds (A+B+C) Increase (+)/Decrease (-)		2235	21	-89
Funds at the beginning of the financial period		35	124	124
Funds at the end of the financial period		2270	145	35

BBS-Bioactive Bone Substitutes Plc

Statement of changes in equity

	Share capital	Share premium account	Invested unrestricted equity fund	Accumulated profits	Equity total
Equity 1/12/2017	80	1 395	7 837	-8 776	536
Profit (loss) of the financial year				1 025	
Paid share issue			3 501		
Equity 30/6/2018	80	1 395	11 338	-7 751	5 062
Equity 1/12/2016	28	1 395	6 977	-4 309	4 091
Profit (loss) of the financial year				-666	
Paid share issue			400		
Equity 30/6/2017	28	1 395	7 377	-4 975	3 825
Equity 1/12/2016	28	1 395	6 977	-4 309	4 091
Profit (loss) of the financial year				-4 467	
Paid share issue	52		860		
Equity 1/12/2017	80	1 395	7 837	-8 776	536